News
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024.
Truist Financial analyst Joon Lee maintained a Hold rating on AnaptysBio (ANAB – Research Report) today. The company’s shares closed last Friday at $23.45. According to TipRanks, Lee is a 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback